Mark S. Blumenkranz, Director at Avalanche Biotechnologies, Inc. ([AAVL]), sold 23,100 shares at $37.35 ($828K) on 2015-06-09, disclosed to the SEC on 2015-06-11.
Scheduled sale ($828k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.52 | 15,300 | $543K | 65.6% |
| 2 | $36.20 | 7,000 | $253K | 30.6% |
| 3 | $37.35 | 200 | $7K | 0.9% |
| 4 | $39.91 | 600 | $24K | 2.9% |
| Total | $35.86 avg | 23,100 | $828K | 100% |
| Filing → |
| AAVL | SELL | 2015-05-21 | $37K | — | Filing → |
| [AAVL] | SELL | 2015-05-18 | $798K | — | Filing → |
| [AAVL] | SELL | 2015-05-13 | $25K | — | Filing → |